» Articles » PMID: 32043021

Cardiac Expression of Factor X Mediates Cardiac Hypertrophy and Fibrosis in Pressure Overload

Abstract

Activated factor X is a key component of the coagulation cascade, but whether it directly regulates pathological cardiac remodeling is unclear. In mice subjected to pressure overload stress, cardiac factor X mRNA expression and activity increased concurrently with cardiac hypertrophy, fibrosis, inflammation and diastolic dysfunction, and responses blocked with a low coagulation-independent dose of rivaroxaban. In vitro, neurohormone stressors increased activated factor X expression in both cardiac myocytes and fibroblasts, resulting in activated factor X-mediated activation of protease-activated receptors and pro-hypertrophic and -fibrotic responses, respectively. Thus, inhibition of cardiac-expressed activated factor X could provide an effective therapy for the prevention of adverse cardiac remodeling in hypertensive patients.

Citing Articles

Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase-Bridging Basic Research to Clinical Findings.

Muric M, Nikolic M, Todorovic A, Jakovljevic V, Vucicevic K Biomolecules. 2024; 14(8).

PMID: 39199344 PMC: 11352257. DOI: 10.3390/biom14080956.


Coagulation Factor Xa Has No Effects on the Expression of PAR1, PAR2, and PAR4 and No Proinflammatory Effects on HL-1 Cells.

Ruf L, Bukowska A, Gardemann A, Goette A Cells. 2023; 12(24).

PMID: 38132169 PMC: 10741780. DOI: 10.3390/cells12242849.


Lysyl oxidase-like 2 processing by factor Xa modulates its activity and substrate preference.

Wang H, Poe A, Martinez Yus M, Pak L, Nandakumar K, Santhanam L Commun Biol. 2023; 6(1):375.

PMID: 37029269 PMC: 10082071. DOI: 10.1038/s42003-023-04748-8.


The Complex Relation between Atrial Cardiomyopathy and Thrombogenesis.

DAlessandro E, Winters J, van Nieuwenhoven F, Schotten U, Verheule S Cells. 2022; 11(19).

PMID: 36230924 PMC: 9563762. DOI: 10.3390/cells11192963.


The Therapeutic Potential of Anticoagulation in Organ Fibrosis.

Oh H, Park H, Song M, Kim H, Baek J Front Med (Lausanne). 2022; 9:866746.

PMID: 35652066 PMC: 9148959. DOI: 10.3389/fmed.2022.866746.


References
1.
Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C . EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature. 2000; 402(6764):884-8. DOI: 10.1038/47260. View

2.
Bauersachs R, Berkowitz S, Brenner B, Buller H, Decousus H, Gallus A . Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010; 363(26):2499-510. DOI: 10.1056/NEJMoa1007903. View

3.
Nicol R, Frey N, Pearson G, Cobb M, Richardson J, Olson E . Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 2001; 20(11):2757-67. PMC: 125475. DOI: 10.1093/emboj/20.11.2757. View

4.
Stanton C, Wallin R . Processing and trafficking of clotting factor X in the secretory pathway. Effects of warfarin. Biochem J. 1992; 284 ( Pt 1):25-31. PMC: 1132692. DOI: 10.1042/bj2840025. View

5.
Bode M, Auriemma A, Grover S, Hisada Y, Rennie A, Bode W . The factor Xa inhibitor rivaroxaban reduces cardiac dysfunction in a mouse model of myocardial infarction. Thromb Res. 2018; 167:128-134. DOI: 10.1016/j.thromres.2018.05.015. View